Literature DB >> 26876917

Synergetic cholesterol-lowering effects of main alkaloids from Rhizoma Coptidis in HepG2 cells and hypercholesterolemia hamsters.

Shuming Kou1, Bing Han1, Yue Wang1, Tao Huang2, Kai He2, Yulong Han1, Xia Zhou2, Xiaoli Ye3, Xuegang Li4.   

Abstract

AIMS: Hyperlipidemia contributes to the progression of cardiovascular diseases. Main alkaloids from Rhizoma Coptidis including berberine (BBR), coptisine (COP), palmatine (PAL), epiberberine (EPI) and jatrorrhizine (JAT), improved dyslipidemia in hypercholesterolemic hamsters to a different degree. In this study, HepG2 cells and hypercholesterolemic hamsters were used to investigate the synergetic cholesterol-lowering efficacy of these five main alkaloids. MAIN
METHODS: The cellular lipid and cholesterol accumulation and in HepG2 cells were evaluated by Oil Red O staining and HPLC analysis. LDL receptor, 3-Hydroxy-3-methylglutaryl CoA reductase (HMGCR) and cholesterol 7-alpha-hydroxylase (CYP7A1) that involving cholesterol metabolism in HepG2 cells were measured by qRT-PCR, western blot and immunofluorescence analysis. The serum profiles including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c), as well as TC and total bile acids (TBA) of feces in hypercholesterolemic hamsters were also measured. KEY FINDING: As compared to single alkaloids, the combination of five main alkaloids (COM) reduced the lipid and cholesterol accumulation in HepG2 cells more effectively and performed an advantageous effect on controlling TC, TG, LDL-c and HDL-c in hypercholesterolemic hamsters. More effective reduction of TBA and TC levels in feces of hamsters were achieved after the administration of COM. These effects were derived from the up-regulation of LDL receptor and CYP7A1, as well as HMGCR downregulation. SIGNIFICANCE: Our results demonstrated that COM showed a synergetic cholesterol-lowering efficacy, which was better than single alkaloids and it might be considered as a potential therapy for hypercholesterolemia.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYP7A1; HMGCR; Hypercholesterolemia; LDL receptor; Rhizoma Coptidis; Synergetic effect

Mesh:

Substances:

Year:  2016        PMID: 26876917     DOI: 10.1016/j.lfs.2016.02.046

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Biologically active isoquinoline alkaloids covering 2014-2018.

Authors:  Xiao-Fei Shang; Cheng-Jie Yang; Susan L Morris-Natschke; Jun-Cai Li; Xiao-Dan Yin; Ying-Qian Liu; Xiao Guo; Jing-Wen Peng; Masuo Goto; Ji-Yu Zhang; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2020-07-29       Impact factor: 12.944

Review 2.  Rhizoma Coptidis: A Potential Cardiovascular Protective Agent.

Authors:  Hui-Li Tan; Kok-Gan Chan; Priyia Pusparajah; Acharaporn Duangjai; Surasak Saokaew; Tahir Mehmood Khan; Learn-Han Lee; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2016-10-07       Impact factor: 5.810

3.  Coptisine from Rhizoma Coptidis Suppresses HCT-116 Cells-related Tumor Growth in vitro and in vivo.

Authors:  Tao Huang; Yubo Xiao; Lin Yi; Ling Li; Meimei Wang; Cheng Tian; Hang Ma; Kai He; Yue Wang; Bing Han; Xiaoli Ye; Xuegang Li
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

4.  The Potential Mechanism of Wuwei Qingzhuo San against Hyperlipidemia Based on TCM Network Pharmacology and Validation Experiments in Hyperlipidemia Hamster.

Authors:  Jianliang Li; Chaolu Wang; Lin Song; Shuzhen Cai; Zhiyong Li; Ya Tu
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-10       Impact factor: 2.629

Review 5.  The Effects and Safety of Chinese Herbal Medicine on Blood Lipid Profiles in Placebo-Controlled Weight-Loss Trials: A Systematic Review and Meta-Analysis.

Authors:  Ann Rann Wong; Angela Wei Hong Yang; Mingdi Li; Andrew Hung; Harsharn Gill; George Binh Lenon
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-17       Impact factor: 2.629

6.  Biological Response Profiling Reveals the Functional Differences of Main Alkaloids in Rhizoma Coptidis.

Authors:  Lan Xie; Shanshan Feng; Xiaoling Zhang; Wenlong Zhao; Juan Feng; Chengmei Ma; Ruijun Wang; Weifang Song; Jing Cheng
Journal:  Molecules       Date:  2021-12-06       Impact factor: 4.411

Review 7.  The Effects of Chunghyul-Dan (A Korean Medicine Herbal Complex) on Cardiovascular and Cerebrovascular Diseases: A Narrative Review.

Authors:  Woo-Sang Jung; Seungwon Kwon; Seung-Yeon Cho; Seong-Uk Park; Sang-Kwan Moon; Jung-Mi Park; Chang-Nam Ko; Ki-Ho Cho
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-02       Impact factor: 2.629

8.  The oral bioavailability, excretion and cytochrome P450 inhibition properties of epiberberine: an in vivo and in vitro evaluation.

Authors:  Ning Chen; Xiao-Yan Yang; Chang-E Guo; Xin-Ning Bi; Jian-Hua Chen; Hong-Ying Chen; Hong-Pin Li; Hong-Ying Lin; Yu-Jie Zhang
Journal:  Drug Des Devel Ther       Date:  2017-12-28       Impact factor: 4.162

9.  Coptisine Induces Apoptosis in Human Hepatoma Cells Through Activating 67-kDa Laminin Receptor/cGMP Signaling.

Authors:  Li Zhou; Fan Yang; Guobing Li; Jingbin Huang; Yali Liu; Qian Zhang; Qin Tang; Changpeng Hu; Rong Zhang
Journal:  Front Pharmacol       Date:  2018-05-18       Impact factor: 5.810

10.  Wu-Mei-wan protects pancreatic β cells by inhibiting NLRP3 Inflammasome activation in diabetic mice.

Authors:  Xueping Yang; Fuer Lu; Lingli Li; Jingbin Li; Jinlong Luo; Siyi Zhang; Xinqiao Liu; Guang Chen
Journal:  BMC Complement Altern Med       Date:  2019-01-31       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.